Amylyx Pharmaceuticals, Inc. (AMLX)
| Market Cap | 3.53B +145.6% |
| Revenue (ttm) | n/a |
| Net Income | -152.09M |
| EPS | -1.43 |
| Shares Out | 125.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,471,272 |
| Open | 27.32 |
| Previous Close | 27.20 |
| Day's Range | 26.94 - 28.60 |
| 52-Week Range | 10.83 - 41.14 |
| Beta | -0.09 |
| Analysts | Strong Buy |
| Price Target | 42.36 (+50.53%) |
| Est. Earnings | Nov 5, 2026 |
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phas... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price target is $42.36, which is an increase of 50.53% from the latest price.
News
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
Amylyx Pharmaceuticals Transcript: Stifel 2026 Virtual Cardiometabolic Forum
Phase III data for avexitide in PBH showed robust efficacy and safety, with a 55% reduction in severe hypoglycemic events and consistent results across endpoints. NDA submission is planned by year-end, targeting a 2027 launch, with a large, growing rare disease market and high physician awareness.
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum.
Amylyx Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Avexitide showed a 55% reduction in severe hypoglycemia for PBH, with robust efficacy and safety, and an NDA submission is planned by year-end. The company is preparing for a 2027 launch, expanding indications, and advancing new collaborations and pipeline assets.
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference.
Amylyx price target raised to $57 from $55 at Guggenheim
Guggenheim raised the firm’s price target on Amylyx (AMLX) to $57 from $55 and keeps a Buy rating on the shares. The firm, which is updating its model for financing…
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,00...
Amylyx price target raised to $42 from $30 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Amylyx (AMLX) to $42 from $30 and keeps an Outperform rating on the shares. The firm citers the positive results…
Amylyx price target raised to $55 from $40 at Guggenheim
Guggenheim raised the firm’s price target on Amylyx (AMLX) to $55 from $40 and keeps a Buy rating on the shares. Avexitide’s striking efficacy and tolerability support strong uptake across…
Amylyx price target raised to $52 from $28 at Baird
Baird raised the firm’s price target on Amylyx (AMLX) to $52 from $28 and keeps an Outperform rating on the shares. The firm updated its model following its clear win…
Amylyx price target raised to $39 from $30 at BofA
Amylyx’s (AMLX) raised the firm’s price target on Bank of America to $39 from $30 and keeps a Buy rating on the shares. Amylyx’s positive Phase 3 LUCIDITY results validate…
Amylyx announces $350M common stock offering
Amylyx (AMLX) Pharmaceuticals announced that it has commenced an underwritten public offering of $350M of shares of its common stock. All of the shares of common stock are being offered…
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 mil...
Amylyx stock soars on GLP-1 success: here's why investors should sell
Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial. The late-stage study evaluate...
Amylyx price target raised to $52 from $28 at Baird
Baird raised the firm’s price target on Amylyx (AMLX) to $52 from $28 and keeps an Outperform rating on the shares.
Amylyx price target raised to $55 from $34 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Amylyx (AMLX) to $55 from $34 and keeps a Buy rating on the shares. Amylyx’s positive LUCIDITY results substantially de-risk avexitide, with…
Amylyx price target raised to $45 from $21 at Stifel
Stifel raised the firm’s price target on Amylyx (AMLX) to $45 from $21 and keeps a Buy rating on the shares. Avexitide’s best-case PBH topline data appear to substantially de-risk…
Amylyx Shares Jump 45% Following Positive Phase 3 Trial Results for GLP-1 Blocker Avexitide
Amylyx Pharmaceuticals ($AMLX) stock jumped 45% to $28.38 in early trading on Tuesday, August 18, after the company reported positive results from its pivotal Phase 3 LUCIDITY clinical trial. The…
Stifel views Amylyx data as ‘best-case scenario’
Stifel says Amylyx (AMLX)’ LUCIDITY results “look excellent.” Avexitide had a “clear win” on the primary endpoint and clean safety and tolerability, the analyst tells investors in a research note.
Amylyx Phase 3 data support FDA approval, says Citi
Citi says Amylyx’s (AMLX) avexitide showed a “highly differentiated” profile in the Phase 3 LUCIDITY study, a 78 participant, placebo-controlled trial evaluating the drug in participants with post-bar...
Amylyx up 28% at $27.50 after announcing Lucidity trial met primary endpoint
08:32 EDT Amylyx (AMLX) up 28% at $27.50 after announcing Lucidity trial met primary endpoint
Amylyx Pharmaceuticals Transcript: Study result
The phase III LUCIDITY trial showed avexitide significantly reduced hypoglycemic events in PBH patients after gastric bypass, meeting all primary and secondary endpoints with a favorable safety profile. The therapy addresses a major unmet need, with high patient and clinician enthusiasm, and is on track for NDA submission and potential U.S. launch in 2027.